Study of Thymoglobulin to Arrest Type 1 Diabetes
This is a phase II study of the safety and efficacy of the rabbit polyclonal anti-thymocyte globulin Thymoglobulin (Thymo) in new onset Type 1 diabetes mellitus (T1DM) to determine if this treatment can induce tolerance and thereby prolong endogenous insulin secretion in affected individuals.
Proleukin & Rapamune in early type 1 diabetes
IL-2 and rapamycin to treat type 1 diabetes within 4 years of diagnosis
This is a phase I trial testing whether two immune system modifying drugs are safe when used in combination and if they can alter the immune system in a way that shows they can halt the progression of type 1 diabetes. This study is for patients who have been diagnosed within the past 3-48 months.
|
